Citigroup Inc Immunovant, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Citigroup Inc holds 31,595 shares of IMVT stock, worth $869,178. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,595

Previous 249,791 87.35%

Holding current value

$869,178

Previous $8.07 Million 89.67%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$25.1 - $31.61 $5.48 Million - $6.9 Million	-218,196 Reduced 87.35%	31,595 $834,000
Q1 2024 May 10, 2024	BUY	$30.27 - $43.79 $3.8 Million - $5.49 Million	125,449 Added 100.89%	249,791 $8.07 Million
Q4 2023 Feb 09, 2024	SELL	$31.31 - $44.19 $61,805 - $87,231	-1,974 Reduced 1.56%	124,342 $5.24 Million
Q3 2023 Nov 09, 2023	BUY	$18.55 - $39.96 $708,220 - $1.53 Million	38,179 Added 43.32%	126,316 $4.85 Million
Q2 2023 Aug 10, 2023	SELL	$14.2 - $23.75 $2.8 Million - $4.68 Million	-197,230 Reduced 69.11%	88,137 $1.67 Million
Q1 2023 May 11, 2023	BUY	$15.27 - $19.72 $2.79 Million - $3.6 Million	182,796 Added 178.21%	285,367 $4.43 Million
Q4 2022 Feb 09, 2023	BUY	$6.59 - $17.75 $656,443 - $1.77 Million	99,612 Added 3366.41%	102,571 $1.82 Million
Q3 2022 Nov 10, 2022	SELL	$3.93 - $6.37 $10,673 - $17,300	-2,716 Reduced 47.86%	2,959 $17,000
Q2 2022 Aug 10, 2022	BUY	$3.38 - $5.65 $1,193 - $1,994	353 Added 6.63%	5,675 $22,000
Q1 2022 May 12, 2022	SELL	$5.06 - $8.77 $754,835 - $1.31 Million	-149,177 Reduced 96.56%	5,322 $29,000
Q4 2021 Feb 10, 2022	SELL	$7.33 - $9.32 $883,631 - $1.12 Million	-120,550 Reduced 43.83%	154,499 $1.32 Million
Q3 2021 Nov 10, 2021	BUY	$7.01 - $11.37 $1.93 Million - $3.13 Million	275,049 New	275,049 $2.39 Million

Others Institutions Holding IMVT

# of Institutions

220

Shares Held

65.1M

Call Options Held

697K

Put Options Held

629K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account